With a PDUFA date less than four weeks away, Urogen Pharma Inc. has been having a rough ride on the Street since the U.S. FDA released a joint briefing document for the May 21 Oncologic Drugs Advisory Committee meeting on UGN-102 (mitomycin).
In what represents just the company’s third PCT filing, Houston-based Starling Medical Inc.’s co-founders, Hannah McKenney and William Hendricks, seek to gain further protection for their at-home urine diagnostic patient-monitoring platform that eliminates the traditional use of catching containers and dipsticks.
Some deubiquitinating enzymes may help protect against cancer, but others appear to promote it. Researchers from the First Affiliated Hospital of Zhejiang University have discovered that the deubiquitinator PSMD14 helps drive bladder cancer, and they have defined at least one signaling pathway through which it works, opening up possibilities for development of new treatments.
Bacillus Calmette-Guérin (BCG) remains the primary treatment for patients with high-risk bladder cancer, but resistance develops in 30% to 40% of cases. The use of oncolytic viruses has emerged as a promising alternative therapeutic strategy.
Evolveimmune Therapeutics Inc. has announced a translational research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to investigate the expression of a new tumor target – UL binding protein 2 (ULBP2) – in muscle-invasive bladder cancer.
Acrivon Therapeutics Inc. provided updated phase II data for checkpoint kinase candidate ACR-368, highlighting promising response rates for biomarker-positive patients with endometrial cancer and raising the possibility of an accelerated pathway in the second-line setting.
Acrivon Therapeutics Inc. provided updated phase II data for checkpoint kinase candidate ACR-368, highlighting promising response rates for biomarker-positive patients with endometrial cancer and raising the possibility of an accelerated pathway in the second-line setting.
Bladder cancers (BCs) that invade the muscle layer are classified as muscle-invasive bladder cancers (MIBCs). The MIBC subtype accounts for around 25% of all BC cases, with a significant proportion of patients presenting distant metastases.
Solid tumors are difficult to treat due to their heterogeneity and limited blood supply, which restrict the effective delivery of anticancer drugs. Macrophages are abundant in solid tumor tissues and are the only cell type actively infiltrating hypoxic tumor regions, making them a promising option for delivering therapeutic agents directly to tumors.
Corbus Pharmaceuticals Inc. has placed its chips on “bets where somebody else is ahead of us,” CEO Yuval Cohen said. “The idea is to have a de-risked asset” that proves better in the clinic. At the 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium in San Francisco, Corbus offered data from the U.S. and U.K. first-in-human dose-escalation study – the Western trial – with Nectin-4-targeting antibody-drug conjugate (ADC) CRB-701 (SYS-6002).
